HEPATITIS C VIRUS INFECTION IN HEMODIALYSIS PATIENTS: COMPARISON OF THE SURABAYA DIALYSIS CENTER AND JUNTENDO UNIVERSITY HOSPITAL DIALYSIS CENTRE
Downloads
Hepatitis C virus infection is highly prevalence in chronic hemodialysis (HD) patients. The present study will compare prevalence of HCV positive population in difference countries where there are great contrasts in and diversity of care available to patients who have end stage renal disease. All serum samples of the 100 patients were tested for HCV antibodies, using third-generation enzyme immunoassay. The prevalence of anti-HCV was correlated with a history of blood transfusion and with duration of hemodialysis. HCV prevalences were 88% of Surabaya group and 6% of Juntendo Group, respectively. In Surabaya Group, prevalence of HCV positive
was high and the risk factors are not only those of the Juntendo Group, but also a combination of poor living conditions, frequent blood transfusions, and lack of adherence. Much needs to be studied about the role of universal screening and effective techniques for primary prevention in Surabaya Group
Problem, Arificial Organs 23: 51–60,1999.
2. Estaben JI, Estaben R, Viladomiou L et al. Hepatitis C virus antibodyHepatitis C virus antibody among risk groups in Spain. Lancet 1989; 334: 294–296.
3. McIntyre PG, McCruden EA, Dow BC et al. Hepatitis C virus
infection in renal dialysis patients in Glasgow. Nephrol Dial Transplant 1994; 9: 291–295.
4. Schneeberger PM, Keur I, Vliet W, Hoek K, Boswijk H, Loon AM,
Dijk WC, Kauffmann RH, Quint W, Doorn LJ. Hepatitis C virus
infection in Dialysis Centers in the Netherlands: a National survey
by serological and molecular methods. J of Clin Microbiology. 1998,
36: 1711–1715.
5. Huraib S, Al-Rashed R, Aldrees A, Aljefry M, Arif M and Al-Faleh
FA. High prevalence of and risk factors for hepatitis C in hemodialysis
Patients in Saudi Arabia: a need for new dialysis strategies. NDT 1995, 10: 470–4.
6. Fujiyama S, Kawano S, Sato S, Shimada H, Matsushita K, Ikezaki
N, Nakano T, Sato T. 1995. Changes in prevalence of anti-HCVChanges in prevalence of anti-HCV antibodies associated with preventive measures among hemodialysis patients and dialysis staff. Hepato-Gastroenterology 42: 162–165.
7. McLaughlin KJ, Cameron SO, Good T, McCruden E, Ferguson JC,
Davidson F, Simmonds P, Mactier RA, McMillan MA. Nosocomial transmission of hepatitis C virus within a British dialysis centre.
Nephrol Dial Transplant 1997, 12: 304–309.
8. Hinrichsen H, Leimenstoll G, Stegen G et al. Prevalence and riskPrevalence and risk factors of hepatitis C virus infection in haemodialysis patients: multicentre study in 2796 patients.Gut 2002, 51: 429–433.
9. Morikawa T, Nakata K, Hamasaki K, et al. Prevalence andPrevalence and characterization of hepatitis C virus in hemodialysis patients. Intern Med 1999; 38: 626–31.
10. Knudsen F, Wantzin P, Rasmussen K, et al. Hepatitis C in dialysisHepatitis C in dialysis patients: Relationship to blood transfusions, dialysis and liver disease. Kidney Int 1993; 43: 1353–6.
11. Sandhu J, Preiksaitis JK, Campbell PM, et al. Hepatitis C prevalence and risk factors in the northern Alberta dialysis population. Am J Epidemiol 1999; 150: 58–66. (Abstract )
12. Dusheiko G, Schmilovitz-Weiss H, Brown D et al. Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease. Hepatology 1994; 19: 13–18.
13. Tokita H, Okamoto H, Iizuka H et al. Hepatitis C virus variants from Hepatitis C virus variants from Jakarta, Indonesia classifiable into novel genotypes in the second (2e and 2f), tenth (10a) and eleventh (11a) genetic groups. J Gen Virol 1996; 77: 293–301.
14. Bosmans JL, Nouwen EJ, Behets G et al. Prevalence and clinical Prevalence and clinical expression of HCV-genotypes in haemodialysis patients of two geographically remote countries: Belgium and Saudi Arabia. Clin Nephrol 1997; 47: 256–262.
15. Medin C, Allander T, Roll M, et al. Seroconversion to hepatitis C virus in dialysis patients. A restropective and prospective study. Nephron 1993; 65: 40–5.
16. Jadoul M, Cornu C, van Ypersele de Strihou C, and UCL Collaboratory Group. Incidence and risk factors for hepatitis C seroconversion in hemodialysis: A prospective study. Kidney Int 1993; 44: 1322–6.
17. Fabrizi F, Martin P, Dixit V, et al. Acquisition of hepatitis C virus inAcquisition of hepatitis C virus in hemodialysis patients: a prospective study by branched DNA signal amplification assay. Am J Kidney Dis 1998; 31: 647–54.
18. Katsoulidou A, Paraskevis D, Kalapothaki V, et al. Molecular Molecular epidemiology of a hepatitis C outbreak in a haemodialysis unit. Multicentre haemodialysis cohort study on viral hepatitis. Nephrol Dial Transplant 1999; 14: 1188–94.
19. Muller G, Zabaletta ME, Arminio A et al. Risk factors for dialysis-Risk factors for dialysisassociated hepatitis C in Venezula. Kidney Int 1992; 41: 1055–8.
20. Yoshida CFT, Takahashi C, Gaspar AMC, Schatzmyr HG, Ruzany
F. Hepatitis C virus in chronic hemodialysis patients with non-A,
non-B hepatitis. Nephron 1992; 60: 150–3.
21. Ponz E, Campistol JM, Bruguera M et al. Hepatitis C infection among kidney transplant recipients. Kidney Int 1991; 40: 748–51.
22. Oguchi H, Miyasaka M, Tokunaga S et al. Hepatitis virus infection (HBV and HCV) in eleven Japanese hemodialysis units. Clin Nephrol 1992; 38: 36–43.
23. Shusterman N, Singer I. Infectious hepatitis in dialysis patients. Am J Kidney Dis 1987; 447–55
24. Hruby Z, Sliwinski J, Molin I, Zalewska M, Knysz B, Czyz W,
Steciwko A, Bogucki J, Gladysz A. High prevalence of antibodies
to hepatitis C virus in three haemodialysis centers in south-western
Poland. Nephrol Dial Transplant 1993, 8: 740–43.
The Indonesian Journal of Tropical and Infectious Disease (IJTID) is a scientific peer-reviewed journal freely available to be accessed, downloaded, and used for research. All articles published in the IJTID are licensed under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which is under the following terms:
Attribution ” You must give appropriate credit, link to the license, and indicate if changes were made. You may do so reasonably, but not in any way that suggests the licensor endorses you or your use.
NonCommercial ” You may not use the material for commercial purposes.
ShareAlike ” If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions ” You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
